Alcon Q1 2023 Earnings Presentation slide image

Alcon Q1 2023 Earnings Presentation

Q1 2023 Vision Care Double-digit Vision Care growth reflects strength in contact lenses and eye drops, including acquired products + + Alcon ● ● ● ● ● Solid global contact lens market growth ALC above-market growth, particularly in US, with silicone hydrogel contact lenses, including Precision 1 and Total product families Price increases across the contact lens portfolio Strong demand for portfolio of eye drops, including Rocklatan and Rhopressa; approximately 5 percentage points of growth contribution to Vision Care from products acquired in 2022 Price increases across the over-the-counter portfolio, including Systane -400 bps of negative impact from FX on Vision Care sales growth 1. Constant currency growth is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix. $916 $557 Net Sales (USD $M) $359 1Q22 $1,029 $615 $414 1Q23 Contact lenses Ocular health (USD) (CC)¹ 12% 10% 14% 15% 16% 14 19%
View entire presentation